



Association of *ADIPOQ* Single Nucleotide Polymorphisms (SNPs) with Obesity Risk in Different Populations: A Systematic Review and Analysis

*Nurgul Sikhayeva*¹, **Akmaral Nursafina*², *Aidana Satayeva*², *Talgat Utupov*¹

1. National Center for Biotechnology, Astana, 010000, Kazakhstan

2. Faculty of Natural Science, Eurasian National University Named After L.N. Gumilyov, Astana, 010000, Kazakhstan

*Corresponding Author: Email: nakmaral@mail.ru

(Received 20 Nov 2023; accepted 18 Feb 2024)

Abstract

Background: Thirty-two single nucleotide polymorphisms (SNPs) are commonly found in *ADIPOQ*. APN levels are decreased in obesity, and SNPs of the *ADIPOQ* gene affecting APN have varying associations with the development of obesity in different populations. This systematic review and meta-analysis aimed to investigate the association of SNPs in *ADIPOQ* with the risk of obesity development in various populations.

Methods: A systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist date up to Feb 2023. We used the Newcastle–Ottawa scale to find out if a study fit the main criteria for submission and to assess the data quality of the articles included in the systematic review and meta-analysis. Odds ratios (OR) and 95% confidence intervals (CI) were calculated via Review Manager (RM) V.5.4 to estimate the connection between *ADIPOQ* polymorphic qualities of a gene and the risk of developing obesity.

Results: The present study analysed the association between *ADIPOQ* polymorphisms (rs1501299, rs2241766, rs266729, rs822393, and rs822396) and obesity risk and suggested that APN is partially responsible for the emergence of obesity and increases its risk.

Conclusion: It is important to take into account several limitations of this meta-analysis when evaluating the findings. First off, even though we looked through numerous databases for all relevant papers, there is a chance we overlooked some. Our capacity to arrive at more firm conclusions was further hampered by the small number of papers that made up our meta-analysis. The most current data, however, are presented in this study since it used newly published data to perform a meta-analysis and evaluate the relationship between *ADIPOQ* polymorphisms and obesity.

Keywords: Obesity risk; Single nucleotide polymorphisms; *ADIPOQ* gene

Introduction

Obesity is a multifactorial metabolic disorder characterized by an abnormal accumulation of adipose tissue, leading to an elevated body mass

index (BMI) (1). Obesity has emerged as a significant global metabolic problem since the 1970s (2, 3). It is associated with several health issues,



including cardiovascular diseases, metabolic syndrome, type 2 diabetes, and colorectal cancer (4, 5). This rise is attributed to a complex interplay of genetic, environmental, and lifestyle factors. It's not solely a result of overeating or lack of physical activity; genetic predispositions can play a significant role in determining an individual's susceptibility to obesity (6). Understanding the genetic basis of obesity is crucial for developing more effective prevention and treatment strategies. One of the genes that have garnered attention in obesity research is the *ADIPOQ* gene, which codes for the hormone adiponectin (APN). APN, a hormone secreted by the adipose tissue, is responsible for fat synthesis and is encoded by the *ADIPOQ* gene (7).

Being overweight or obese is a serious global public health issue and the fifth biggest risk factor for deaths worldwide (8). Overaccumulation of visceral adipose tissue has been identified as a major driving factor for type 2 diabetes (9). By secreting adipokines, the adipose tissue plays a significant role in regulating metabolic balance. The adipokine APN, which is generated by adipocytes, has anti-inflammatory and insulin-sensitizing qualities (10). Numerous prospective studies have linked a decreased incidence of diabetes to high levels of circulating APN.

Low molecular weight (LMW), moderate molecular weight (MMW), and high molecular weight (HMW) are the three polymorphic variants of APN that are in circulation (11). It's interesting that plasma glucose levels and the ratio of plasma HMW APN to total APN associated more strongly than with any of the other forms. Strong connections have been observed between the APN gene (*ADIPOQ*/*APM1*/*GBP* 28) locus 3q27 and a number of metabolic diseases, including type 2 diabetes, dyslipidemia, obesity, and poor glucose tolerance. Its SNPs also have a strong correlation with obesity.

Obesity affects various cell types in different tissues, particularly pancreatic β -cells, kidneys, and heart, and regulates the genes responsible for liver gluconeogenesis. Additionally, APN improves insulin sensitivity by affecting primary metabolic

tissues and overall energy homeostasis of the body (12).

The *ADIPOQ* gene encodes APN and is located at the chromosomal locus 3q27. It consists of 244 amino acids and contains three exons and two introns (13). Thirty-two single nucleotide polymorphisms (SNPs) are commonly found in *ADIPOQ* (14). APN levels are decreased in obesity, and SNPs of the *ADIPOQ* gene affecting APN have varying associations with the development of obesity in different populations. With the escalating global burden of obesity and its associated comorbidities, elucidating the genetic factors contributing to its development is of importance.

This systematic review and meta-analysis aimed to investigate the association of SNPs in *ADIPOQ* with the risk of obesity development in various populations.

Methods

The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist (20) was followed in conducting the systematic review. The following were the requirements for qualifying in the source studies:

Inclusion criteria

- Case-control studies
- Studies that looked into the association between SNPs of the *ADIPOQ* gene and the possibility of developing obesity in different people
- Researches that provided information on genotypes and allele frequencies

Exclusion criteria

- Systematic reviews, meta-analyses, and repeated studies- Articles that did not examine the association between *ADIPOQ* polymorphisms and risk of obesity development
- Studies in which it was not possible to determine whether the control population was in Hardy-Weinberg equilibrium

Articles were searched by published date up to Feb 2023 in PubMed, Google Scholar, Web of

Science, and Cochrane Library databases using the terms “obesity”, “adiponectin”, “ADIPOQ”, “SNP”, and “polymorphism”. Based on the search results, only human-based articles were selected. Two authors independently selected the search results based on the eligibility criteria. The collected studies were entered into Rayyan. After removing duplicate articles, the remaining articles' titles and abstracts were scrutinized.

The following data were extracted from the selected articles: first author's name, year of publication, population ethnicity, number of cases and controls, and genotype frequency. One author conducted data collection and analysis.

Risk of bias

To determine whether a study met the inclusion criteria and to assess the data quality of the articles included in the systematic review and meta-analysis, the Newcastle–Ottawa scale was used. The articles were assessed independently by two researchers to determine the quality of nonrandomised studies. The results of the examination were discussed, and articles were selected based on their scores on the Newcastle–Ottawa scale (15). The total scores ranged from zero to nine, with scores above six indicating high quality (Table 1).

Table 1: Newcastle-Ottawa scale

| <i>Study</i> | <i>Selection</i> | | | | <i>Comparability</i> | | <i>Exposure</i> | <i>Total</i> |
|-------------------|----------------------------|-----------------------------------|-------------------------|-------------------------|---|--|---|--------------|
| | Ade-quate case defini-tion | Repre-sentative-ness of the cases | Selec-tion of con-trols | Defini-tion of controls | Study con-trols for the most important factor | Study con-trols for any addi-tional fac-tors | Assertain-ment of the exposure (max of 2 stars) | |
| Beebe-Dimmer (16) | * | * | * | * | * | * | ** | 8 |
| De Luis (17) | * | * | * | * | * | * | ** | 8 |
| Boumaiza (18) | * | * | * | * | * | * | ** | 7 |
| Elghazy (19) | * | * | * | * | * | * | ** | 7 |
| Hsiao (20) | * | * | * | * | * | * | ** | 8 |
| Kaur (21) | * | * | * | * | * | * | ** | 8 |
| Ramya (22) | * | * | * | * | * | * | ** | 8 |
| Romero (23) | * | * | * | * | * | * | ** | 8 |
| Vankova (24) | * | * | * | * | * | * | ** | 7 |
| Zaki (25) | * | * | * | * | * | * | ** | 7 |
| Zayani (26) | * | * | * | * | * | * | ** | 7 |

Statistical analysis

Odds ratios (OR) and 95% confidence intervals (CI) were calculated using Review Manager (RM)

v. 5.4 to estimate the relationship between *ADIPOQ* gene polymorphisms and the risk of obesity. The pooled OR was performed for the domi-

nant, recessive, and over-dominant models. The Chi-square-based Q and I-squared tests were used to analyse heterogeneity ($P < 0.10$). Heterogeneity between studies was evaluated using the I² test: when I² was $< 50\%$, the fixed-effects model was used; if I² was $> 50\%$ to 90% , a random-effects model was used. Publication bias was assessed using a funnel plot. Review Manager ver. 5.4 was used to perform all the analyses and calculations.

OR = 1 Exposure does not affect odds of outcome

OR > 1 Exposure associated with higher odds of outcome

OR < 1 Exposure associated with lower odds of outcome

The CI value estimates the precision of the OR value. However, unlike the *P*-value, the 95% CI does not report a measure's statistical signifi-

cance, as a small CI indicates a higher precision of the OR.

Results

To investigate the association of SNPs of the ADIPOQ gene with the risk of obesity development, here were matches between 1540 PubMed articles, 30 Cochrane Library articles, 31 Web of Science database items, and 4500 Google Scholar articles, including 600 research results. First, 136 articles were selected from the databases by analysing their titles and abstracts. During the secondary examination, articles that did not meet the eligibility criteria were reduced, including 87 articles that did not show an association between polymorphisms and obesity, 31 that did not show genotype frequency, and 18 that were not case-control studies (Fig. 1).




Fig. 1: Flowchart of study selection

rs1501299 polymorphism and obesity risk

Nine studies (7, 8, 9, 15, 16, 17, 18, 20, 23) were analysed to determine the association between the rs1501299 polymorphism and obesity risk. There were no significant associations between rs1501299 and obesity under dominant (OR=0.77, 95% CI=0.56–1.07), recessive

(OR=0.66, 95% CI=0.47–0.92), and over-dominant (OR=0.95, 95% CI=0.70–1.28) genetic models. However, in the subgroup analysis, the Tunisian population showed a significant association with obesity risk under the dominant model (OR=1.65, 95% CI=1.28–2.14) (Table 2).

Table 2: Main characteristics of included studies, distribution of genotypes and subgroup analysis of rs1501299

| Population | Author | Year | Sample size | GG | | GT | | TT | | Dominant comparison | Recessive comparison | Over-dominant comparison |
|------------------|-------------------|------|-------------|-------|---------|-------|---------|-------|---------|---------------------|----------------------|--------------------------|
| | | | | Obese | Control | Obese | Control | Obese | Control | | | |
| Punjabi | Kaur (21) | 2018 | 250/300 | 140 | 185 | 66 | 81 | 44 | 34 | 0.79(0.56-1.11) | 0.60(0.37-0.97) | 0.97(0.66-1.42) |
| Egyptian | Elghazy (19) | 2019 | 100/97 | 16 | 52 | 38 | 37 | 43 | 11 | 0.18(0.09-0.35) | 0.16(0.07-0.33) | 1.10(0.62-1.95) |
| French | De Luis (17) | 2006 | 1229/1350 | 545 | 688 | 457 | 488 | 91 | 79 | 0.82(0.70-0.96) | 0.74(0.54-1.01) | 1.13(0.66-1.33) |
| Tunisian | Zayani (26) | 2016 | 721/400 | 156 | 201 | 136 | 397 | 108 | 123 | 1.65(1.28-2.14) | 0.56(0.41-0.75) | 0.42(0.30-0.54) |
| African-american | Beebe-Dimmer (16) | 2010 | 131/344 | 37 | 100 | 45 | 97 | 19 | 25 | 0.71(0.43-1.14) | 0.55(0.29-1.05) | 1.04(0.64-1.66) |
| Tunisian | Boumaiza (18) | 2011 | 160/169 | 97 | 88 | 54 | 60 | 9 | 21 | 1.42(0.91-2.20) | 2.38(1.06-5.37) | 0.93(0.59-1.46) |
| South Indian | Ramya (22) | 2013 | 1100/100 | 552 | 667 | 242 | 206 | 24 | 22 | 0.71(0.58-0.87) | 0.83(0.46-1.50) | 1.41(1.13-1.74) |
| Egyptian | Zaki (25) | 2014 | 104/100 | 2 | 15 | 45 | 44 | 57 | 41 | 0.11(0.02-0.50) | 0.57(0.33-1.00) | 0.97(0.56-1.69) |
| Bulgarian | Vankova (24) | 2014 | 67/97 | 35 | 47 | 25 | 36 | 7 | 13 | 1.14(0.61-2.13) | 1.34(0.51-3.57) | 0.99(0.52-1.89) |

rs2241766 and obesity risk

Six studies (7, 8, 15, 17, 18, 22) were analysed to determine the association between the rs2241766 polymorphism and risk of obesity. There were no significant associations under dominant (OR=0.85, 95% CI=0.67–1.08) and recessive

(OR=0.84, 95% CI=0.69–1.01) models. Association with obesity risk was observed under the over-dominant model (OR=1.05, 95% CI=0.94–1.18), especially in the Tunisian population (OR=1.68, 95% CI=0.94–3.01) (Table 3).

Table 3: Main characteristics of included studies, distribution of genotypes and subgroup analysis of rs2241766

| Population | Author | Year | Sample size | TT | | TG | | GG | | Dominant comparison | Recessive comparison | Over-dominant comparison |
|------------------|-------------------|------|-------------|-------|---------|-------|---------|-------|---------|---------------------|----------------------|--------------------------|
| | | | | Obese | Control | Obese | Control | Obese | Control | | | |
| Egyptian | Elghazy (19) | 2019 | 100/97 | 251 | 443 | 123 | 244 | 26 | 34 | 1.06(0.82-1.36) | 0.71(0.42-1.20) | 0.87(0.67-1.13) |
| Tunisian | Zayani (26) | 2016 | 721/400 | 16 | 52 | 38 | 37 | 31 | 25 | 0.28(0.14-0.53) | 0.49(0.26-0.92) | 1.68(0.94-3.01) |
| African-American | Beebe-Dimmer (16) | 2010 | 131/344 | 93 | 204 | 10 | 21 | 0 | 0 | 0.96(0.43-1.21) | Not estimable | 1.04(0.47-2.31) |
| French | De Luis (17) | 2006 | 1229/1350 | 841 | 957 | 270 | 275 | 23 | 26 | 0.90(0.75-1.09) | 1.02(0.58-1.80) | 1.12(0.92-1.35) |
| Tunisian | Boumaiza (18) | 2011 | 160/169 | 104 | 105 | 48 | 56 | 8 | 8 | 1.13(0.72-1.77) | 0.94(0.35-2.58) | 0.86(0.54-1.38) |
| Mexican | Romero (23) | 2015 | 724/745 | 189 | 225 | 350 | 349 | 168 | 161 | 0.83(0.66-1.04) | 0.90(0.70-1.15) | 1.08(0.88-1.33) |

rs266729 and obesity risk

Six studies (7, 8, 15, 17, 18, 23) were analysed to determine the association between rs266729 polymorphism and obesity risk. rs266729 showed a significant association with obesity risk among other *ADIPOQ* polymorphisms and genetic models (OR=1.15, 95% CI=0.91–1.45) under the dominant genetic model. Association with obesity risk under the dominant model was detected for the Egyptian population (OR=3.55, 95% CI=1.89–6.67) (Table 4).

rs822393 and obesity risk

Data from the three studies (7, 8, 17) were analysed to determine the association between

rs822393 and the risk of obesity. After pooling the data, a strong association with obesity risk was identified in the over-dominant genetic model (OR = 1.29, 95% CI = 0.97–1.70). However, other two genetic models did not show association with obesity risk (recessive comparison: OR = 0.99, 95% CI = 0.83–1.19; dominant comparison: OR = 0.78, 95% CI = 0.65–0.95). In the subgroup analysis, the Tunisian population showed a strong association with obesity development risk under the over-dominant model (OR = 1.77, 95% CI = 1.38, 2.27) (Table 5).

Table 4: Main characteristics of included studies, distribution of genotypes and subgroup analysis of rs266729

| Population | Author | Year | Sample size | CC | | CG | | GG | | Dominant comparison | Recessive comparison | Over-dominant comparison |
|------------------|-------------------|------|-------------|-------|---------|-------|---------|-------|---------|---------------------|----------------------|--------------------------|
| | | | | Obese | Control | Obese | Control | Obese | Control | | | |
| Egyptian | Elghazy (19) | 2019 | 100/97 | 77 | 52 | 18 | 44 | 2 | 4 | 3.55(1.89-6.67) | 1.98(0.35-11.06) | 0.29(0.15-0.55) |
| African-american | Beebe-Dimmer (16) | 2010 | 131/344 | 104 | 248 | 24 | 62 | 3 | 4 | 1.03(0.62-1.69) | 0.55(0.12-2.49) | 0.91(0.54-1.54) |
| French | De Luis (17) | 2006 | 1229/1350 | 713 | 704 | 435 | 524 | 64 | 98 | 1.26(1.08-1.48) | 1.43(1.03-1.98) | 0.86(0.73-1.01) |
| South Indian | Ramya (22) | 2011 | 1100/1100 | 521 | 670 | 326 | 485 | 49 | 67 | 1.14(0.96-1.36) | 1.00(0.69-1.46) | 0.87(0.73-1.04) |
| Mexican | Romero (23) | 2015 | 724/745 | 253 | 289 | 346 | 347 | 112 | 97 | 0.85(0.69-1.05) | 0.82(0.61-1.09) | 1.05(0.86-1.30) |
| Taiwanese | Hsiao (20) | 2016 | 388/663 | 129 | 463 | 88 | 289 | 20 | 58 | 0.90(0.67-1.20) | 0.84(0.49-1.42) | 1.06(0.79-1.44) |

Table 5: Main characteristics of included studies, distribution of genotypes and subgroup analysis of rs822393

| Population | Author | Year | Sample size | CC | | CT | | TT | | Dominant comparison | Recessive comparison | Over-dominant comparison |
|--------------|-------------|------|-------------|-------|-----------|-------|-----------|-------|-----------|---------------------|----------------------|--------------------------|
| | | | | Obese | Non-obese | Obese | Non-obese | Obese | Non-obese | | | |
| Mexican | Romero (23) | 2015 | 724/745 | 189 | 225 | 350 | 349 | 168 | 161 | 0.83(0.66-1.04) | 0.90(0.70-1.15) | 1.08(0.88-1.33) |
| Tunisian | Zayani (26) | 2016 | 721/400 | 173 | 394 | 195 | 252 | 32 | 75 | 0.63(0.49-0.81) | 1.34(0.87-2.06) | 1.77(1.38-2.27) |
| South Indian | Ramya (22) | 2011 | 1100/1100 | 418 | 601 | 340 | 425 | 67 | 90 | 0.88(0.73-1.05) | 0.99(0.71-1.38) | 1.14(0.95-1.37) |

rs822396 and obesity risk

Three studies (7, 8, 19) were analysed to determine the association between rs822396 and obesity risk. Higher association with obesity risk was observed under the over-dominant model (OR=1.07, 95% CI=0.92–1.24) in comparison

with the dominant (OR=0.85, 95% CI=0.73–0.99) and recessive models (OR=0.84, 95% CI=0.69–1.01). In subgroup analysis, high OR was observed in the African-American population under the recessive model (OR=2.34, 95% CI=0.50–10.87) (Table 6).

Table 6: Main characteristics of included studies, distribution of genotypes and subgroup analysis of rs822396

| Population | Author | Year | Sample size | AA | | AG | | GG | | Dominant comparison | Recessive comparison | Over-dominant comparison |
|------------------|-------------------|------|-------------|-------|-----------|-------|-----------|-------|-----------|---------------------|----------------------|--------------------------|
| | | | | Obese | Non-obese | Obese | Non-obese | Obese | Non-obese | | | |
| Punjabi | Kaur (21) | 2018 | 250/300 | 114 | 148 | 105 | 134 | 31 | 18 | 0.86(0.61-1.21) | 0.45(0.25-0.83) | 0.90(0.64-1.26) |
| African-american | Beebe-Dimmer (16) | 2010 | 131/344 | 70 | 139 | 32 | 79 | 2 | 10 | 1.32(0.81-2.15) | 2.34(0.50-10.87) | 0.84(0.51-1.38) |
| South Indian | Ramya (22) | 2011 | 1100/1100 | 355 | 540 | 400 | 495 | 107 | 120 | 0.80(0.67-0.95) | 0.82(0.62-1.08) | 1.15(0.97-1.38) |

Discussion

Adipose tissue secretes plasma APN, with *ADIPOQ* being the only significant gene expressing it. The increased phosphorylation and activity of AMP-activated protein kinase and peroxisome proliferator-activated receptor- α activity are believed to be mediated by APN, which binds to APN receptors (AdipoR1 and AdipoR2) to activate glucose uptake and fatty acid oxidation in both skeletal and cardiac muscles (7). APN replacement in humans is a promising strategy for treating and preventing type 2 diabetes and obesity. APN-deficient animals show signs of insulin resistance (8, 29). Individuals with obesity had lower plasma APN levels compared to lean patients, and that weight loss could considerably raise these levels. The present study analysed the association between *ADIPOQ* polymorphisms (rs1501299, rs2241766, rs266729, rs822393, and rs822396) and obesity risk and suggested that APN is involved in the development of obesity and increases its risk (Table 7). Previous studies have reported potential roles of other APN polymorphisms of genes in patients who have diabetes of the second type and obesity. The association between rs1501299 and rs266729 polymorphisms of *ADIPOQ* gene, and type 2 diabetes mellitus in an Iranian population was analysed (27). By looking at the results we can determine that the APN polymorphism of rs266729 gene with SNP – 11,377 C > G is strongly connected with the risk of obesity in the population of Iran;

however, the same was not observed for the rs1501299 (SNP + 276 G > T) polymorphism. We noticed the same tendency for *ADIPOQ* rs1501299, which was strongly correlated with obesity in Caucasians (9) but not in Nigerians (25). However, this meta-analysis suggests that the *ADIPOQ* rs266729 polymorphism is most significantly associated with obesity and its risk of development.

Although obesity is ubiquitous, research has shown prevalence patterns based on ethnicity and SNPs (8). For instance, in the population of Mexico, the only gene to show a protective association with obesity was rs11061971 of *ADIPOQ2*, and there was no correlation noticed between the rs2241766 polymorphism of *ADIPOQ* and obesity (28, 29). In contrast, studies have established that the rs2241766 polymorphism is associated with obesity in the Chinese population (7, 30).

While this study provides valuable insights into the association between *ADIPOQ* polymorphisms and obesity risk, it is important to consider several limitations of this meta-analysis when evaluating the findings. First off, even though we looked through numerous databases for all relevant papers, there is a chance we overlooked some. Our capacity to arrive at more firm conclusions was further hampered by the small number of papers that made up our meta-analysis.

Table 7: Pooled ORs and 95% CIs of the associations between ADIPOQ SNPs and obesity risk

| <i>Polymorphism</i> | <i>Total</i> | <i>Heterogeneity</i> | <i>Dominant model P-value OR (95%CI)</i> | <i>Recessive model P-value OR (95%CI)</i> | <i>Over-dominant model P-value OR (95%CI)</i> |
|---------------------|--------------|---|--|---|---|
| rs1501299 | 3090/3858 | Dominant: I ² = 87% Recessive: I ² = 73% Over-dominant: I ² = 86% | 0.77 [0.56, 1.07] | 0.66 [0.47, 0.92] | 0.95 (0.70- 1.28) |
| rs2241766 | 2589/3222 | Dominant: I ² = 68% Recessive: I ² = 1% Over-dominant: I ² = 13% | 0.85 [0.67, 1.08] | 0.84 [0.69, 1.01] | 1.05 (0.94- 1.18) |
| rs266729 | 3284/4505 | Dominant: I ² = 79% Recessive: I ² = 39% Over-dominant: I ² = 68% | 1.15 [0.91, 1.45] | 1.02 [0.85, 1.21] | 0.87 (0.72- 1.06) |
| rs822393 | 1932/2572 | Dominant: I ² = 57% Recessive: I ² = 17% Over-dominant: I ² = 81% | 0.78 [0.65, 0.95] | 0.99 [0.83, 1.19] | 1.29 (0.97- 1.70) |
| rs822396 | 1216/1683 | Dominant: I ² = 44% Recessive: I ² = 61% Over-dominant: I ² = 25% | 0.85 [0.73, 0.99] | 0.75 [0.41, 1.36] | 1.07 (0.92- 1.24) |

The most current data, however, are presented in this study since it used newly published data to perform a meta-analysis and evaluate the relationship between ADIPOQ polymorphisms and obesity.

Despite this limitation, the study possesses several notable strengths that contribute to its significance. Firstly, this study offers a comprehensive analysis of the relationship between ADIPOQ polymorphisms and obesity risk. Furthermore, the study employs various genetic models, including dominant, recessive, and over-dominant models, to assess the association between ADIPOQ polymorphisms and obesity risk. Lastly, the study's focus on specific ADIPOQ polymorphisms (e.g., rs1501299, rs2241766, rs266729)

narrows its scope and allows for a more targeted investigation of the genetic variants affecting obesity risk. These results advance understanding of the genetic underpinnings of obesity and contribute valuable insights to the field of genetic epidemiology.

Conclusion

The findings of this analysis underscore the complexity of genetic factors contributing to obesity and emphasize the importance of exploring specific genetic variants.

The present study analysed the association between ADIPOQ polymorphisms (rs1501299, rs2241766, rs266729, rs822393, and rs822396) and

obesity risk and suggested that APN raises the risk of obesity and contributes to its development.

One potential perspective is the development of more personalized approaches to obesity prevention and management. Understanding how specific *ADIPOQ* polymorphisms influence obesity risk can lead to tailored interventions and treatments based on an individual's genetic profile.

Additionally, as genetic data becomes more accessible and affordable, larger-scale studies with diverse populations can be conducted to validate and extend the current findings. Collaborative efforts across multiple research institutions can enhance the robustness and generalizability of genetic associations.

Journalism Ethics considerations

Ethical issues (Including plagiarism, informed consent, misconduct, data fabrication and/or falsification, double publication and/or submission, redundancy, etc.) have been completely observed by the authors.

Acknowledgements

This research was funded by grants (AP09057948) from the Science Committee of the Ministry of Science and Higher Education of the Republic of Kazakhstan.

Conflict of interest

The authors declare that there is no conflict of interests.

References

1. Smetanin E, Outlev K, Kruchinin E, Yanin E, Zaitsev E (2022). The Dynamics of Lipid Metabolism in Patients with Morbid Obesity Depending On the Type of Performed Surgery. *Georgian Med News*, (322): 105–108.
2. García Pacheco AV, Arévalo Peláez CE, Ortiz Benavides RE (2022). The pharmacological treatment of obesity: A historical perspective.

3. Selvakumaran S, Lin CY, Hadgraft N, Chandrabose M, Owen N, Sugiyama T (2023). Area-level socioeconomic inequalities in overweight and obesity: Systematic review on moderation by built-environment attributes. *Health Place*, 83: 103101.
4. Jadhav AD, Chobe SV (2022). Risk assessment of cardiovascular diseases using kNN and decision tree classifier. *Revue d'Intelligence Artificielle*, 36(1): 155-161.
5. Global Burden of Metabolic Risk Factors for Chronic Diseases Collaboration (BMI Mediated Effects), Lu Y, Hajifathalian K, Ezzati M, Woodward M, Rimm EB, Danaei G (2014). Metabolic mediators of the effects of body-mass index, overweight, and obesity on coronary heart disease and stroke: a pooled analysis of 97 prospective cohorts with 1.8 million participants. *Lancet*, 383 (9921): 970-83.
6. Alnuaimi J, Al-Za'abi A, Yousef IA, Belghali M, Liftawi SM, Shraim ZF, Tayih EAM (2023). Effect of a health-based physical activity intervention on university students' physically active behaviors and perception. *Int J Sustain Dev Plan*, 18(5): 1451-1456.
7. Ergören MC, Söyler G, Sah H, et al (2019). Investigation of potential genomic biomarkers for obesity and personalized medicine. *Int J Biol Macromol*, 122: 493-8.
8. Wu J, Liu Z, Meng K, et al (2014). Association of adiponectin gene (*ADIPOQ*) rs2241766 polymorphism with obesity in adults: a meta-analysis. *PLoS One*, 9 (4): e95270.
9. Palit SP, Patel R, Jadeja SD, et al (2020). A genetic analysis identifies a haplotype at adiponectin locus: association with obesity and type 2 diabetes. *Sci Rep*, 10 (1): 2904.
10. Alharbi MS, Khabour OF, Alomari MA (2023). The association between adiponectin plasma level and rs1501299 *ADIPOQ* polymorphism with atrial fibrillation. *J King Saud Univ Sci*, 35(4): 102655.
11. Wang ZV, Scherer PE (2016). Adiponectin, the past two decades. *J Mol Cell Biol*, 8 (2):93-100.
12. Al-Harithy RN, Al-Zahrani MH (2012). The adiponectin gene, *ADIPOQ*, and genetic sus-

- ceptibility to colon cancer. *Oncol Lett*, 3 (1): 176-80.
13. Moher D, Liberati A, Tetzlaff J, et al (2009). Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. *PLoS Med*, 6 (7): e1000097.
 14. Hasni D, Ilmiawati C, Firdawati F, Lipoeto NI (2023). Possible correlations between SH2B3 rs2078863 gene polymorphism, lifestyle, food habits, and nutritional intake of Minangkabau females with hypertension. *Adv Life Sci*, 10(4):609-618.
 15. Stang A (2010). Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. *Eur J Epidemiol*, 25 (9): 603-5.
 16. Beebe-Dimmer JL, Zuhlke KA, Ray AM, et al (2010). Genetic variation in adiponectin (ADIPOQ) and the type 1 receptor (ADIPOR1), obesity and prostate cancer in African Americans. *Prostate Cancer Prostatic Dis*, 13 (4): 362-8.
 17. de Luis DA, Primo D, Izaola O, et al (2019). Role of the variant in adiponectin gene rs266729 on weight loss and cardiovascular risk factors after a hypocaloric diet with the Mediterranean pattern. *Nutrition*, 60: 1-5.
 18. Boumaiza I, Omezzine A, Rejeb J, et al (2011). Association between eight adiponectin polymorphisms, obesity, and metabolic syndrome parameters in Tunisian volunteers. *Metab Syndr Relat Disord*, 9 (6): 419-26.
 19. Elghazy AM, Elsaied AM, Refaat M, et al (2022). Biochemical studies of adiponectin gene polymorphism in patients with obesity in Egyptians. *Arch Physiol Biochem*, 128 (1): 43-50.
 20. Hsiao TJ, Lin E (2016). A validation study of adiponectin rs266729 gene variant with type 2 diabetes, obesity, and metabolic phenotypes in a Taiwanese population. *Biochem Genet*, 54 (6): 830-41.
 21. Kaur H, Badaruddoza B, Bains V, et al (2018). Genetic association of ADIPOQ gene variants (-3971A>G and +276G>T) with obesity and metabolic syndrome in North Indian Punjabi population. *PLoS One*, 13 (9): e0204502.
 22. Ramya K, Ayyappa KA, Ghosh S, et al (2013). Genetic association of ADIPOQ gene variants with type 2 diabetes, obesity and serum adiponectin levels in south Indian population. *Gene*, 532 (2): 253-62.
 23. Peralta Romero JJ, Karam Araujo R, Burguete García AI, et al (2015). ADIPOQ and ADIPOR2 gene polymorphisms: association with overweight/obesity in Mexican children. *Bol Med Hosp Infant Mex*, 72 (1): 26-33.
 24. Vankova D, Radanova M, Kiselova-Kaneva Y, et al (2015). The FTO rs9939609, ADIPOQ rs1501299, rs822391, and ADIPOR2 rs16928662 polymorphisms relationship to obesity and metabolic syndrome in Bulgarian sample. *Biotechnol Biotechnol Equip*, 26: 65.
 25. Zaki ME, El-Salam M, Hassan NA, et al (2014). Association of adiponectin gene polymorphisms 276 G>T with obesity and biochemical parameters in adolescents. *Int J Pharm Pharm Sci*, 6 (5): 226-9.
 26. Zayani N, Omezzine A, Boumaiza I, et al (2017). Association of ADIPOQ, leptin, LEPR, and resistin polymorphisms with obesity parameters in Hammam Sousse Sahloul heart study. *J Clin Lab Anal*, 31 (6): e22148.
 27. Alimi M, Goodarzi MT, Nekoei M (2021). Association of ADIPOQ rs266729 and rs1501299 gene polymorphisms and circulating adiponectin level with the risk of type 2 diabetes in a population of Iran: a case-control study. *J Diabetes Metab Disord*, 20 : 87-93.
 28. Ogundele OE, Adekoya KO, Osinubi AAA, et al (2018). Association of adiponectin gene (ADIPOQ) polymorphisms with measures of obesity in Nigerian young adults. *Egypt J Medical Hum Genet*, 19 (2): 123-7.
 29. López DJE, Urbaneja H (2020). Tolerancia a la glucosa e insulinemia en hermanos asintomáticos de pacientes diabéticos tipo 2. *Gaceta Médica De Caracas*, 114(4): 305-317.
 30. Abuhendi N, Qush A, Naji F, Abunada H, Al Buainain R, Shi Z, Zayed H (2019). Genetic polymorphisms associated with type 2 diabetes in the Arab world: A systematic review and meta-analysis. *Diabetes Res Clin Pract*, 151: 198-208.